New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
07:14 EDTGSK, ISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
News For ISIS;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
11:04 EDTISISIsis Pharmaceuticals partnership deal generally expected, says Piper Jaffray
Piper Jaffray noted that Isis Pharmaceuticals (ISIS) had been indicating a high level of interest in its FXIrx anti-clotting antisense program ahead of announcing its deal with Bayer (BAYRY) and the firm believes the announcement of a partnership pact was generally expected. The firm said it already included "meaningful" economics from the FXI program in its valuation for Isis and maintains a Neutral rating on the stock, which is up 4.6% to $60.92 in morning trading.
09:03 EDTISISIsis Pharmaceuticals enters into license agreement with Bayer HealthCare
Subscribe for More Information
May 3, 2015
18:11 EDTGSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
07:43 EDTGSKExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:59 EDTGSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
16:54 EDTISISIsis Pharmaceuticals earns $10M milestone payment from Biogen
Subscribe for More Information
15:20 EDTGSKGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTGSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
07:21 EDTGSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
April 27, 2015
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSKTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTGSKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:32 EDTISISJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 22, 2015
16:25 EDTISISIsis Pharmaceuticals reports positive data from ISIS-TTR Rx
Subscribe for More Information
April 20, 2015
07:20 EDTGSK, ISISAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use